Paquinimod, Possible Scleroderma Therapy, Shows Promise in Small Trial

Paquinimod, Possible Scleroderma Therapy, Shows Promise in Small Trial

305170

Paquinimod, Possible Scleroderma Therapy, Shows Promise in Small Trial

Eight weeks of treatment with a small molecule called paquinimod significantly reduced the number of myofibroblasts — cells that drive scarring — in people with scleroderma, a small clinical trial reported. Findings also suggested that paquinimod may lessen type I interferon (IFN) activity, a relevant scleroderma biomarker, and appeared to be well-tolerated by patients. The study, “An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod,” was published in the…

You must be logged in to read/download the full post.